Conference|American Academy of Allergy, Asthma & Immunology - Dermatology Casale discussed data from the phase 3 LIBERTY-CSU CUPID studies evaluating dupilumab’s use in urticaria.This is a modal window. The Playback API request failed for an unknown reason...
Following positive phase 2 results in asthma, the phase 3 Liberty Asthma QUEST trial was initiated to provide further evidence for dupilumab efficacy and safety in patients with uncontrolled, moderate-to-severe asthma. Methods Liberty Asthma QUEST is a phase 3, multinational, multicenter, randomized,...
Dupilumab (Dupixent, Sanofi and Regeneron) significantly reduced exacerbations compared with placebo in children ages 6-11 years who had moderate-to-severe asthma in a phase 3 trial. A fully human monoclonal antibody, dupilumab also improved lung function vs placebo by week 12, an improvement that...
Phase 2a randomized clinical trial of dupilumab (anti-IL-4Ralpha) for alopecia areata patients. PMID: 34460948 Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis. PMID: 35636689 Efficacy and s...
In the Phase 3 LIBERTY ASTHMA QUEST study (NCT02414854) which enrolled patients aged ≥12 years with uncontrolled, moderate-to-severe asthma, add-on dupilumab almost halved the annualized rate of severe asthma exacerbations (AER) over the course of the 52-week treatment period.Citation4Additionally...
Surya Bhatt, MD, MSPH, medical director of the Pulmonary Function and Exercise Physiology Lab at the University of Alabama at Birmingham, explained that the phase 3 NOTUS trial results highlighted challenges in diagnosingchronic obstructive pulmonary disease (COPD)with type 2 inflammation. He also no...
Allergic bronchopulmonary aspergillosis (ABPA) is a severe hypersensitivity reaction to aspergillus species colonizing the airways of patients with asthma or cystic fibrosis. Biologics including anti-IgE and anti-IL5 antibodies have strongly changed the
Both phase 2 and 3 trials demonstrated a decline in severity as assessed by the EASI-50 in 65–80% of the patients [33,34]. So far, dupilumab has been studied in bronchial asthma [36] and in AD, but it seems likely that it may have an effect in other eosinophilic dermatoses ...
Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis Gastroenterology, 158 (2020), pp. 111-122 View in ScopusGoogle Scholar Cited by (35) The future of targeted therapy in chronic spontaneous urticaria 2024, Annals of Allergy, Asthma and Immunology Ci...
efficacy and acceptable safety in CRSwNP and other type 2 diseases (eg, atopic dermatitis and asthma). We now report the local effects of dupilumab on type 2 inflammatory biomarkers in nasal secretions and nasal polyp tissues of patients with CRSwNP in a randomized, placebo-controlled, phase 2 ...